1. Home
  2. companies
  3. dulaglutide

dulaglutide

FDA Approves Lilly's Once-Weekly Shot For Diabetes
FDA Approves Lilly's Once-Weekly Shot For Diabetes
Forbes
FDA
Eli Lilly
diabetes
Trulicity
dulaglutide
Novo chief Sorensen preps for showdown as Lilly's dulaglutide nears diabetes market
Novo chief Sorensen preps for showdown as Lilly's dulaglutide nears diabetes market
Fierce Biotech
dulaglutide
Novo Nordisk
Eli Lilly
Lars Sorenson
diabetes
Lilly's head-to-head with Victoza raises a red flag for diabetes drug dulaglutide
Lilly's head-to-head with Victoza raises a red flag for diabetes drug dulaglutide
Fierce Biotech
Victoza
Eli Lilly
diabetes
dulaglutide
Will Cymbalta Break Eli Lilly?
Will Cymbalta Break Eli Lilly?
Seeking Alpha
Eli Lilly
Cymbalta
dulaglutide
patents
Evista
China
Can Diabetes Treatments Replace Patent Losses At Eli Lilly & Co?
Can Diabetes Treatments Replace Patent Losses At Eli Lilly & Co?
Motley Fool
Eli Lilly
diabetes
patents
dulaglutide
GLP-1 agonist
Novo Nordisk
AstraZeneca
GSK
JNJ
Eli Lilly Gains Slightly on Dulaglutide Data
Eli Lilly Gains Slightly on Dulaglutide Data
Yahoo/Zacks.com
Eli Lilly
dulaglutide
diabetes
Who loses most in Lilly vs. Novo diabetes study? AstraZeneca
Who loses most in Lilly vs. Novo diabetes study? AstraZeneca
Fierce Pharma
Victoza
Novo Nordisk
Eli Lilly
dulaglutide
diabetes
Bydureon
AstraZeneca
Clock Is Ticking For AstraZeneca
Clock Is Ticking For AstraZeneca
Forbes
AstraZeneca
dulaglutide
GSK
Eli Lilly
Bydureon
diabetes
Lilly weekly diabetes drug succeeds vs market leader Victoza -study
Lilly weekly diabetes drug succeeds vs market leader Victoza -study
Yahoo/Reuters
Eli Lilly
diabetes
Victoza
Novo Nordisk
dulaglutide
Could These Potential Catalysts Drive Lilly Higher?
Could These Potential Catalysts Drive Lilly Higher?
Motley Fool
Eli Lilly
Evista
Zyprexa
Cymbalta
generics
solanezumab
Alzheimer's disease
LY2963016
diabetes
empagliflozin
dulaglutide
Eli Lilly: 2014 Predictions
Eli Lilly: 2014 Predictions
Seeking Alpha
Eli Lilly
dulaglutide
empagliflozin
solanzemab
ramucirumab
Evista
Gemzar
3 New Diabetes Drugs Possibly on the Way Soon
3 New Diabetes Drugs Possibly on the Way Soon
Motley Fool
diabetes
Forixga
AstraZeneca
Bristol-Myers Squibb
dulaglutide
Eli Lilly
Afrezza
MannKind
Eli Lilly Hopes To End Novo Nordisk's Stranglehold On The GLP-1 Market
Eli Lilly Hopes To End Novo Nordisk's Stranglehold On The GLP-1 Market
Seeking Alpha
Novo Nordisk
diabetes
Eli Lilly
GLP-1 agonist
AstraZeneca
Bristol-Myers Squibb
dulaglutide
Victoza
Is This What the Doctor Ordered for Eli Lilly?
Is This What the Doctor Ordered for Eli Lilly?
Motley Fool
Eli Lilly
diabetes
dulaglutide
JNJ
Merck
Novo Nordisk
Bristol-Myers Squibb
Pipeline Vs. Expiring Patents: Eli Lilly's Future
Pipeline Vs. Expiring Patents: Eli Lilly's Future
Seeking Alpha
Eli Lilly
patents
empagliflozin
dulaglutide
ixekizumab
ramucirumab
Novo Nordisk shares hit by concerns over rival diabetes drugs
Novo Nordisk shares hit by concerns over rival diabetes drugs
Reuters
diabetes
Novo Nordisk
Sanofi
Eli Lilly
dulaglutide
Victoza
Lyxumia
Lantus
Eli Lilly's Big Bet On Diabetes
Eli Lilly's Big Bet On Diabetes
Seeking Alpha
Eli Lily
diabetes
insulin
LY2605541
dulaglutide
LY2963016
empagliflozin
Clean Superiority Sweep For Dulaglutide Could Reshape Diabetes Market
Clean Superiority Sweep For Dulaglutide Could Reshape Diabetes Market
Seeking Alpha
diabetes
Eli Lilly
dulaglutide
Novo Nordisk
Sanofi
Lilly diabetes drug as good as insulin in study
Lilly diabetes drug as good as insulin in study
Reuters
Eli Lilly
insulin
diabetes
dulaglutide
3 Diabetes Phase 3 Wins
3 Diabetes Phase 3 Wins
Motley Fool
Merck
Sanofi
Eli Lilly
diabetes
AstraZeneca
Bristol-Myers Squibb
dulaglutide
Amylin

Click here to subscribe to daily news headlines in your email inbox